GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees ...

1 in 5 Americans will develop skin cancer in their lifetime – AAD INVESTOR OVERVIEW NASDAQ: SRTS August 2024 SAFE HARBOR STATEMENT Forward-Looking Statements This presentation includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximatel ...

Group 1 - Accuray Incorporated will participate in the Jefferies Global Healthcare Conference 2025, with a scheduled fireside chat on June 4th, 2025, at 5:30pm EDT/2:30pm PDT [1] - A live webcast of the conference call will be available on the company's Investor Relations website, with a replay accessible for 90 days [1] Group 2 - Accuray is focused on advancing radiation therapy to improve patient outcomes, offering innovative solutions for complex cases and simplifying treatment for more common cases [2] - The company is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, collaborating with clinicians and administrators to enhance patient recovery [2] - Accuray is headquartered in Madison, Wisconsin, and has facilities worldwide [2]

Core Insights - Shuttle Pharmaceuticals is focused on improving outcomes for cancer patients treated with radiation therapy, with significant progress in its Phase 2 clinical trial for Ropidoxuridine in glioblastoma treatment [1][2] - The company is also advancing its Diagnostics subsidiary through a research agreement with UCSF and has filed a provisional patent for PSMA-targeted therapies [1][2] Phase 2 Clinical Trial Highlights - Nearly 50% of patient enrollment achieved in the initial randomized portion of the trial [2] - 84% of enrolled patients completed all seven cycles of treatment [2] - Ropidoxuridine has been well-tolerated, with reported toxicity no greater than 2 on a scale of 1-5 [2] - Analysis of pharmacokinetic and pharmacodynamic samples has begun to optimize dosing and response [2] - Enrollment continues at recognized cancer centers, with the objective to finalize enrollment later this year and data readouts anticipated in 2026 [2] Diagnostics Subsidiary Developments - A sponsored research agreement with UCSF aims to develop a PSMA-targeted ligand for theranostic applications in prostate cancer [1][2] - A provisional patent application for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy" has been filed in collaboration with Dr. Alan Kozikowski [1][2] Corporate Governance and Financial Position - Three new board members have been appointed to enhance the company's strategic direction [1][2] - The company has strengthened its balance sheet through a recent public offering, with cash and cash equivalents reported at $4.5 million as of March 31, 2025 [2]

More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in ...

Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments SoonerMADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an ...